secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001937653-25-000076
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks Q3 2025 revenue $27.6M, net loss narrows to $19.6M; positive ZW191 data
--------------------------------------------------------------------------------

- Revenue $27.6M (up from $16.0M YoY) driven by $25.0M J&J milestone; net loss $19.6M vs $29.9M.
- Cash resources $299.4M as of Sep 30, 2025; projected runway into 2H-2027 including anticipated milestones.
- Encouraging Phase 1 data for ZW191 (FRα ADC): 53% objective response rate (64% in gynecological cancers).
- First patient dosed in Phase 1 trial of ZW251 (GPC3-targeting ADC) for hepatocellular carcinoma.
- Completed $22.7M in share repurchases (1.44M shares at avg $15.80) under remaining $30.0M program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765325000076/0001937653-25-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765325000076/zyme-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001937653-25-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer